SCHEMBL30928463

SCHEMBL30928463

Cc1cc([C@H](C)O)c2oc(-c3cnn(C)c3)c(Cl)c(=O)c2c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 1/20 0.36
▸ MET P08581 1/20 0.35
▸ PIK3CA P42336 2/20 0.35
▸ PDK2 Q15119 1/20 0.34
▸ CDK2 P24941 7/20 0.33
▸ CDK1 P06493 2/20 0.33
▸ S1PR2 O95136 1/20 0.33
▸ IDH1 O75874 2/20 0.33
▸ MAP4K1 Q92918 1/20 0.32
▸ TERT O14746 1/20 0.32
▸ AURKA O14965 1/20 0.32
▸ TTK P33981 1/20 0.32
▸ AURKB Q96GD4 1/20 0.32
▸ INCENP Q9NQS7 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.32
▸ HSP90AB1 P08238 1/20 0.32
▸ AKT1 P31749 1/20 0.31
▸ AKT2 P31751 1/20 0.31
▸ AKT3 Q9Y243 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30928408 0.89 ACLY (0.37) ACLYPIK3CAPDK2CDK2CDK1
SCHEMBL30928402 0.89 ACLY (0.37) ACLYPIK3CAPDK2CDK2CDK1
SCHEMBL30889635 0.87 ACLY (0.36) ACLYMETPIK3CAPDK2CDK2
SCHEMBL30889717 0.85 PIK3CA (0.38) ACLYPIK3CACDK2CDK1MAP4K1
SCHEMBL31319794 0.79 PIM1 (0.40) ACLYMETPDK2
SCHEMBL30889633 0.79 PIK3CA (0.44) ACLYPIK3CA
SCHEMBL26888425 0.78 PIK3CA (0.64) PIK3CAAKT1AKT2AKT3
SCHEMBL27137719 0.78 PIK3CA (0.64) PIK3CAAKT1AKT2AKT3
SCHEMBL30742327 0.78 PIK3CA (0.64) PIK3CAAKT1AKT2AKT3
SCHEMBL31481682 0.78 AURKA (0.35) ACLYMETPIK3CACDK2MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION 2024-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 ACLY 2561/4885MET 2494/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback